A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522831-33-00

Enrollment

Registered

2026-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis Suppurativa

Brief summary

Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16, assessed as proportion of participants who achieve HiSCR75 at Week 16. Hidradenitis Suppurativa Clinical Response 75 is defined as at least a 75% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline.

Detailed description

HiSCR50 at Week 16, assessed as proportion of participants who achieve HiSCR50 at Week 16., Incidence of treatment emergent adverse events (TEAEs) throughout the trial.

Interventions

DRUGZASOCITINIB

DRUGMatching Placebo for TAK-279

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16, assessed as proportion of participants who achieve HiSCR75 at Week 16. Hidradenitis Suppurativa Clinical Response 75 is defined as at least a 75% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline.	—

Secondary

Measure	Time frame
HiSCR50 at Week 16, assessed as proportion of participants who achieve HiSCR50 at Week 16., Incidence of treatment emergent adverse events (TEAEs) throughout the trial.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 7, 2026